Sugi Predict

Sugi Predict / Compounds / SCHEMBL2279227

SCHEMBL2279227

SCHEMBL2279227

Cc1ccc(S(=O)(=O)n2ccc3c(Cl)c(C(=O)O)cnc32)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ BRD4 O60885 1/20 0.42
▸ PTPN11 Q06124 1/20 0.41
▸ PDE4A P27815 2/20 0.39
▸ PDE4B Q07343 2/20 0.39
▸ PDE4C Q08493 2/20 0.39
▸ PDE4D Q08499 2/20 0.39
▸ PKM P14618 1/20 0.38
▸ PPARG P37231 5/20 0.38
▸ PPARD Q03181 5/20 0.38
▸ PPARA Q07869 5/20 0.38
▸ GRM4 Q14833 2/20 0.37
▸ PTGDR2 Q9Y5Y4 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ ALDH3A1 P30838 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ NOD1 Q9Y239 1/20 0.37
▸ CA12 O43570 3/20 0.37
▸ CA1 P00915 3/20 0.37
▸ CA2 P00918 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2732260 0.88 L3MBTL1 (0.44) L3MBTL1BRD4PDE4APDE4BPDE4C
SCHEMBL1933804 0.86 KDM4E (0.49) L3MBTL1POLBNOD1CA12CA1
SCHEMBL16052697 0.84 L3MBTL1 (0.51) L3MBTL1BRD4PTPN11PDE4APDE4B
SCHEMBL1356064 0.84 L3MBTL1 (0.51) L3MBTL1BRD4PDE4APDE4BPDE4C
SCHEMBL30509477 0.84 L3MBTL1 (0.51) L3MBTL1BRD4PTPN11PDE4APDE4B
SCHEMBL1748728 0.81 L3MBTL1 (0.49) L3MBTL1BRD4PTPN11PDE4APDE4B
SCHEMBL20535940 0.81 L3MBTL1 (0.49) L3MBTL1BRD4PTPN11PDE4APDE4B
SCHEMBL1776849 0.81 L3MBTL1 (0.55) L3MBTL1BRD4PTPN11PKMPPARG
SCHEMBL28735169 0.80 MEN1 (0.52) PPARGPPARDPPARANR3C1
SCHEMBL1933799 0.80 L3MBTL1 (0.47) L3MBTL1BRD4PTPN11PDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11826365-B2 Type II raf kinase inhibitors DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-11-28 — — US disclosed
US-11826365-B2 Type II raf kinase inhibitors DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-11-28 — — US disclosed
US-20200297721-A1 TYPE II RAF KINASE INHIBITORS DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-09-24 — — US disclosed
EP-2937345-B1 TYPE II RAF KINASE INHIBITORS DANA FARBER CANCER INST INC (US) 2018-03-21 — — EP disclosed
US-9358231-B2 Type II RAF kinase inhibitors DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-06-07 — — US disclosed
US-9358231-B2 Type II RAF kinase inhibitors DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-06-07 — — US disclosed
US-9358231-B2 Type II RAF kinase inhibitors DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-06-07 — — US disclosed
US-20160046636-A1 TYPE II RAF KINASE INHIBITORS DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-02-18 — — US disclosed
US-20160046636-A1 TYPE II RAF KINASE INHIBITORS DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-02-18 — — US disclosed
US-20160046636-A1 TYPE II RAF KINASE INHIBITORS DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-02-18 — — US disclosed
US-20150157629-A1 TYPE II RAF KINASE INHIBITORS DANA-FARBER CANCER INSTITUTE, INC. (US) 2015-06-11 — — US disclosed
US-20150157629-A1 TYPE II RAF KINASE INHIBITORS DANA-FARBER CANCER INSTITUTE, INC. (US) 2015-06-11 — — US disclosed
EP-2519517-B1 TYPE II RAF KINASE INHIBITORS DANA FARBER CANCER INST INC (US) 2015-03-25 — — EP disclosed
EP-2519517-B1 TYPE II RAF KINASE INHIBITORS DANA FARBER CANCER INST INC (US) 2015-03-25 — — EP disclosed
US-20130040949-A1 TYPE II RAF KINASE INHIBITORS DANA-FARBER CANCER INSTITUTE, INC. (US) 2013-02-14 — — US disclosed
US-20130040949-A1 TYPE II RAF KINASE INHIBITORS DANA-FARBER CANCER INSTITUTE, INC. (US) 2013-02-14 — — US disclosed
US-20130040949-A1 TYPE II RAF KINASE INHIBITORS DANA-FARBER CANCER INSTITUTE, INC. (US) 2013-02-14 — — US disclosed
EP-2519517-A2 TYPE II RAF KINASE INHIBITORS Dana-Farber Cancer Institute, Inc. (US) 2012-11-07 — — EP disclosed
WO-2011090738-A2 TYPE II RAF KINASE INHIBITORS DANA-FARBER CANCER INSTITUTE, INC. (US) 2011-07-28 — — WO disclosed
WO-2011090738-A2 TYPE II RAF KINASE INHIBITORS DANA-FARBER CANCER INSTITUTE, INC. (US) 2011-07-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11826365-B2 Type II raf kinase inhibitors BRAF, RAF1, ARAF L3MBTL1 1340/4885BRD4 630/4885PTPN11 625/4885
US-20150157629-A1 TYPE II RAF KINASE INHIBITORS BRAF, RAF1, ARAF L3MBTL1 1340/4885BRD4 630/4885PTPN11 625/4885
US-20200297721-A1 TYPE II RAF KINASE INHIBITORS BRAF, RAF1, ARAF L3MBTL1 1340/4885BRD4 630/4885PTPN11 625/4885
US-20160046636-A1 TYPE II RAF KINASE INHIBITORS BRAF, RAF1, ARAF L3MBTL1 1340/4885BRD4 630/4885PTPN11 625/4885
US-20130040949-A1 TYPE II RAF KINASE INHIBITORS BRAF, RAF1, ARAF L3MBTL1 1340/4885BRD4 630/4885PTPN11 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.